Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2011

View Archived Issues

Roche discovers novel class of inhibitors of the hexosamine biosynthesis pathway

U.K. study describes distribution of transient receptor potential TRPA1 channel in human lung

Novel engineered physiocrine has thrombopoietic effects in vivo

Large-scale phase III trial assesses ChimeriVax-Dengue vaccine in Singapore

Valeant Pharmaceuticals reports phase III data on efinaconazole

Promising results emerge from first phase III tedizolid trial in ABSSSI

Antisense therapy enters phase I trial in children with spinal muscular atrophy

Ardea Biosciences initiates phase III lesinurad program

Trimel Pharmaceuticals announces completion of phase II TBS-2 trial in anorgasmia

Hanmi and Kinex sign Orascovery licensing agreement

Xarelto obtains E.U. approval in two new indications

Enrollment complete in first phase III migalastat hydrochloride trial

Lundbeck reports on MAA for Selincro

AbGenomics to regain rights to immunotherapeutic for psoriasis and other immunological diseases

NewGen Therapeutics acquires targeted oncology programs

Phase I trials evaluate candidate prime-boost malaria vaccine regimen in healthy adults and children

Canadian university prepares new prostanoid EP4 receptor agonists

Novel epidermal growth factor receptor inhibitors synthesized by Chinese university

New lysophospholipid S1P1 receptor ligands patented by the Institute of Materia Medica

Hande Starlake Bioscience prepares new PARP inhibitors

Boehringer Ingelheim discloses new chemokine CCR2 receptor antagonists

FDA approves fixed-dose combination tablet for treatment of hypertension

FDA accepts tofacitinib NDA for review

Orexo reports novel pharmacokinetic findings for breakthrough cancer pain treatment

BioDelivery Sciences reports on confirmatory BEMA-buprenorphine/naloxone trial

Novartis stops phase III aliskiren hemifumarate trial

Takeda to expand oncology pipeline with acquisition of Intellikine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...